Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABS.OL
- Price
- 3.41
- Stock movement down
- -0.08 (-2.31%)
- Company name
- Arctic Bioscience AS
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 91.38M
- Ent value
- 183.94M
- Price/Sales
- 5.31
- Price/Book
- 0.47
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 63.00%
- 1 year return (CAGR)
- 16.90%
- 3 year return (CAGR)
- -32.45%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-12
DIVIDENDS
ABS.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.31 |
| Price to Book | 0.47 |
| EV to Sales | 10.69 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.96M |
| EPS (TTM) | -0.88 |
| FCF per share (TTM) | -0.96 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 17.20M |
| Gross profit (TTM) | 5.59M |
| Operating income (TTM) | -24.18M |
| Net income (TTM) | -23.52M |
| EPS (TTM) | -0.88 |
| EPS (1y forward) | -0.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 32.48% |
| Operating margin (TTM) | -140.57% |
| Profit margin (TTM) | -136.69% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.49M |
| Net receivables | 10.53M |
| Total current assets | 55.22M |
| Goodwill | 1.63M |
| Intangible assets | 209.74M |
| Property, plant and equipment | 32.94M |
| Total assets | 290.35M |
| Accounts payable | 15.54M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 66.84M |
| Total liabilities | 95.05M |
| Shareholder's equity | 195.30M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.60M |
| Capital expenditures (TTM) | 153.66K |
| Free cash flow (TTM) | -25.76M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -12.04% |
| Return on Assets | -8.10% |
| Return on Invested Capital | -11.34% |
| Cash Return on Invested Capital | -12.42% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.24 |
| Daily high | 3.39 |
| Daily low | 3.24 |
| Daily Volume | 7K |
| All-time high | 490.00 |
| 1y analyst estimate | 15.00 |
| Beta | 1.30 |
| EPS (TTM) | -0.88 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ABS.OL | S&P500 | |
| Current price drop from All-time high | -99.30% | -0.89% |
| Highest price drop | -99.66% | -56.47% |
| Date of highest drop | 21 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -93.63% | -10.86% |
| Avg time to new high | 74 days | 12 days |
| Max time to new high | 1089 days | 1805 days |
COMPANY DETAILS
Marketcap
91.38M
Marketcap category
Small-cap
Description
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
Employees
22
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets remain mixed, with the pan-European STOXX Europe 600 Index ending roughly flat amid ongoing trade discussions, investors are keeping a close watch on economic indicators and geopol...
July 25, 2025
Amid renewed uncertainty about U.S. trade policy and escalating geopolitical tensions in the Middle East, the European market has seen a decline, with major stock indexes such as Germany’s DAX and Fra...
June 16, 2025
As European markets navigate a landscape of mixed economic signals, including hopes for easing trade tensions and fluctuating interest rates, investors are increasingly looking at diverse opportunitie...
May 16, 2025